GlaxoSmithKline (NYSE: GSK) announced that the European Commission has approved a variation to expand the current therapeutic indication for Volibris® ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE